{"id":"NCT03601637","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del","officialTitle":"A Phase 3, 2-part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-07","primaryCompletion":"2021-10-29","completion":"2021-10-29","firstPosted":"2018-07-26","resultsPosted":"2023-01-06","lastUpdate":"2023-01-06"},"enrollment":61,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"LUM","otherNames":["lumacaftor","VX-809"]},{"type":"DRUG","name":"IVA","otherNames":["ivacaftor","VX-770"]}],"arms":[{"label":"Part A: LUM/IVA","type":"EXPERIMENTAL"},{"label":"Part B: LUM/IVA","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and pharmacokinetics (PK) of lumacaftor (LUM) and ivacaftor (IVA) in participants 1 to less than 2 years of age with cystic fibrosis (CF), homozygous for F508del (F/F).","primaryOutcome":{"measure":"Part A: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA","timeFrame":"Day 1 and Day 15","effectByArm":[{"arm":"Part A: LUM 75 mg/IVA 94 mg","deltaMin":14600,"sd":5560},{"arm":"Part A: LUM 100 mg/IVA 125 mg","deltaMin":12600,"sd":7190}],"pValues":[]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":27,"countries":["United States","Canada"]},"refs":{"pmids":["37983082","35771568","33331662"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Cough","Pyrexia","Rhinorrhoea","Vomiting","Infective pulmonary exacerbation of cystic fibrosis"]}}